Compare Enbridge Inc (ENB) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enbridge Inc vs IDEXX Laboratories, Inc. — how do they compare? Enbridge Inc trades at $46.6 (market cap $103.38B), while IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B). The key difference: Enbridge Inc is far larger — about 2.6× IDEXX Laboratories, Inc.'s market cap, and Enbridge Inc pays a 6.02% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enbridge Inc for 91 Days and IDEXX Laboratories, Inc. for 46 Days on average.
| ENB | IDXX | |
|---|---|---|
Market Cap | $103.38B | $40.43B |
Volume | 3,684,305 | 692,164 |
Sector | Energy | Health |
52-Week High | $58.04 | $766.68 |
52-Week Low | $45.23 | $504.70 |
Typical Hold Time | 91 Days | 46 Days |
Enterprise Value | $185.39B | $41.32B |
Dividend Yield | 6.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENB trades at $46.54, up 1.42% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $65.19B in 2025, and the dividend yield is attractive at approximately 6% based on the recent $0.97 payout. Analyst consensus is mixed with a $61.63 price target, indicating potential upside from current levels.
The outlook for ENB is supported by stable cash flows and a secured project backlog, but risks include high debt levels and sensitivity to interest rates. Investment opportunity lies in the dividend income and valuation discount to analyst targets, though investors face headwinds from energy market volatility and rising leverage.
IDEXX Laboratories (IDXX) trades at $513.14, up 1.28% with strong fundamentals including 25.03% net income margin and 74.21% ROE. The stock shows bearish technical signals but maintains consistent earnings beats and analyst consensus of $665 price target. Recent acquisition of CoVetAI expands AI capabilities in veterinary workflow intelligence, supporting long-term growth framework.
Outlook remains positive with revenue growth accelerating to $4.3B in 2025 and projected $4.6B in 2026. Key risks include foreign exchange headwinds and weaker U.S. veterinary visits. The 56.5% buy rating from analysts suggests continued confidence in the company's diagnostic innovation pipeline and recurring revenue economics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enbridge Inc
Enbridge owns extensive midstream assets that transport hydrocarbons across the U.S. and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also owns and operates a regulated natural gas utility and Canada's largest natural gas distribution company. Finally, the firm has a small renewables portfolio primarily focused on onshore and offshore wind projects.
Read more on ENB →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
